Navigation Links
Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
Date:5/9/2013

, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.  Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements can be identified by words
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
4. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
5. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
6. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
8. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
9. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
10. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
11. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014  Rebiotix Inc. announced this morning that results of ... RBX2660 (microbiota suspension) will be presented in two posters and ... Philadelphia from October 8-12. ... session on Thursday, October 9, 2014: Poster: RBX2660 ... Interim Analysis of the PUNCH-CD Phase 2 Safety Study ...
(Date:9/17/2014)... 17, 2014  Bayer HealthCare will present data on ... th Annual Meeting, which takes place September 18-20 ... which will be shared through poster presentations, showcase Bayer,s ... Data will be presented in a scientific forum. ... in hemophilia A patients, Bayer is maintaining its commitment ...
(Date:9/17/2014)... September 17, 2014 According to ... Component (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU), by ... Wellness), and by Geography - Global Forecast to 2020", ... market is expected to reach $56.50 Billion by 2020, ... 2020. Browse 235 market data Tables and ...
Breaking Medicine Technology:PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4
... (Nasdaq: ENDP ) today announced that it will present ... 2011 at 3:45 p.m. ET.  Dr. Ivan Gergel executive vice president ... programs. The presentation will be webcast live and can ... investors section.   About Endo ...
... nation,s leading retail pharmacy, brings its "To Your Health" ... Texas. The program will provide free preventive health screenings ... through November as a way to help citizens determine ... a path to better health. (Logo: ...
Cached Medicine Technology:CVS/pharmacy Debuts the 'To Your Health' Program in Dallas and Fort Worth Texas, Bringing More Than 80 Free Health Screening Events to the Community 2CVS/pharmacy Debuts the 'To Your Health' Program in Dallas and Fort Worth Texas, Bringing More Than 80 Free Health Screening Events to the Community 3
(Date:9/18/2014)... 18, 2014 One Week Kitchens will have ... Bloomsburg Fair beginning this Saturday. Their display will be inside ... example of the products and design services that are offered ... countertops for fair-goers to see. This display won ‘Most Beautiful ... this year and really is something to see. , ...
(Date:9/18/2014)... Each year, Norman Regional Hospital in Norman, ... National Health IT (NHIT) Week to celebrate the contributions ... Regional show its gratitude, Access, the leading provider ... giveaway items to support their NHIT Week program. , ... free lunches, Norman Regional is spending time this week ...
(Date:9/18/2014)... Lake City, Utah (PRWEB) September 18, 2014 ... Now Spoonful of Comfort, an online food delivery service provider, ... , New Country Fresh Tomato Basil soup is a nod ... begins, of course, with a tangy tomato base, then Spoonful ... asiago and parmesan cheeses. A flashback to childhood has never ...
(Date:9/18/2014)... Computer Resources of America, Inc. (CRA), ... York City, has been awarded a contract to provide ... with stores in over 150 countries. The services will ... being the retailer’s dispatch arm handling all IT support ... Chief Executive Officer of CRA said, “We are excited ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 With ... have special functions of adjusting human body physiology, ... won great popularity with a variety of specific ... food in China reached RMB187.4 billion, up 12.0% ... during 2006-2013. , View Full Report at ...
Breaking Medicine News(10 mins):Health News:One Week Kitchens Taking Display to Bloomsburg Fair 2Health News:Access Helps Norman Regional Hospital Celebrate Its Staff During National Health IT Week 2014 2Health News:An Old Classic Brings New Soup Delivery Options to Spoonful of Comfort 2Health News:CRA Awarded Managed Support Contract for Global Retailer 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 3Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 4
... steps to see that the woman who sued them for ?250,000 ... eventually gave birth to her daughter Jayde and sued the Perth ... ,However, the Perth Sheriff Court was told that ... abortion would be successful. Ms Dow had the procedure done in ...
... prescribed to treat Parkinson’s disease revealed shocking results. After ... Parkinson's disease could turn patients into compulsive gamblers. Scientists ... association between pathological gambling and the drugs. ... the brain. Dopamine is a chemical that is naturally ...
... from urinary incontinence are more likely to be depressed, says ... until you get to a restroom. The condition is twice ... and can happen for various medical reasons. ,The ... condition alone and doctors 'need to be attentive to these ...
... Medical Council (GMC) here has warned a doctor of Indian ... at his clinic// because he was an asylum seeker in ... the man treatment because "he was not British and did ... ,Chandra, who studied medicine in India and has ...
... worthwhile to consider kicking the smoking habit, even at older ... enhances the risk of dying in middle age for both ... of premature death. The study, which scores very high, one ... this subject, that studies the habit of smoking and its ...
... might be fun for kids may lead to bacterial ... conducted on petting zoos and feeding animals//. The results ... unaware that simple preventive measures such as hand washing ... three such similar studies would be presented at the ...
Cached Medicine News:Health News:Petting Zoos Can Lead To Bacterial Infection And Illness 2
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride. 1.5% agararose...
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Inoculum Broth with Calcium Chloride and Phytone....
Medicine Products: